Aarti Drugs Q3 FY26: 20% interim dividend, 9M standalone PAT up 34%

Pat Growth 25pctResults View source PDF Explain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.0%Reaction day

₹393.40

prior close

₹356.30

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.3%-7.3% vs market

Pharmaceuticals peers, median of 155sector+0.2%-6.2% vs sector

On the reaction day the stock moved 7.3 pts less than Nifty Microcap 250 and 6.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.9

15m

+2.0

30m

+2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.0+1.3-7.3+0.2-6.2

Next day

-4.5+0.3-4.8-0.4-4.2

-4.7-0.5-4.2-1.1-3.6

-4.3+2.1-6.4+0.7-5.0

-4.1+3.1-7.2+1.3-5.4

-4.7+2.6-7.3+1.5-6.1

-5.7+0.6-6.2+0.3-6.0

15d

-5.8-1.4-4.4-2.3-3.6

-8.4-6.9-1.5-5.1-3.3

-9.6-7.7-1.9-7.9-1.7

+0.7+7.0-6.3+0.8-0.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved audited Q3 and 9M FY26 results on Feb 3, 2026. Standalone 9M PAT rose to Rs. 122.7 cr from Rs. 91.3 cr, up 34% YoY. Total income 9M grew to Rs. 1,629 cr from Rs. 1,551 cr. Q3 standalone revenue dipped to Rs. 529 cr from Rs. 579 cr. New Sayakha plant started Sep 2025. Interim dividend of Rs. 2 per share (20%) declared; record date Feb 9, 2026.

Likely market impact

Strong 9M profit growth and dividend payout are positives. Q3 revenue dip and Sayakha plant ramp-up are key things to watch.